ATE291089T1 - Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen - Google Patents

Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Info

Publication number
ATE291089T1
ATE291089T1 AT99940986T AT99940986T ATE291089T1 AT E291089 T1 ATE291089 T1 AT E291089T1 AT 99940986 T AT99940986 T AT 99940986T AT 99940986 T AT99940986 T AT 99940986T AT E291089 T1 ATE291089 T1 AT E291089T1
Authority
AT
Austria
Prior art keywords
capsid proteins
hpv types
producing yeast
yeast expressed
expressed hpv
Prior art date
Application number
AT99940986T
Other languages
English (en)
Inventor
Daniela Tornese Buonamassa
Catherine E Greer
Cesira L Galeotti
Giuliano Bensi
Roberto Petracca
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22258285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291089(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE291089T1 publication Critical patent/ATE291089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99940986T 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen ATE291089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9662598P 1998-08-14 1998-08-14
PCT/US1999/018016 WO2000009699A2 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins

Publications (1)

Publication Number Publication Date
ATE291089T1 true ATE291089T1 (de) 2005-04-15

Family

ID=22258285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940986T ATE291089T1 (de) 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Country Status (5)

Country Link
EP (1) EP1105495B2 (de)
AT (1) ATE291089T1 (de)
CA (1) CA2340422C (de)
DE (1) DE69924262T3 (de)
WO (1) WO2000009699A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
JP2001506485A (ja) * 1996-10-04 2001-05-22 メルク エンド カンパニー インコーポレーテッド 合成ｈｐｖ１６ウイルス様粒子

Also Published As

Publication number Publication date
CA2340422C (en) 2010-03-16
WO2000009699A9 (en) 2000-07-27
WO2000009699A2 (en) 2000-02-24
DE69924262D1 (de) 2005-04-21
EP1105495B2 (de) 2009-01-21
WO2000009699A3 (en) 2000-05-18
DE69924262T3 (de) 2009-07-23
DE69924262T2 (de) 2006-01-26
CA2340422A1 (en) 2000-02-24
EP1105495A2 (de) 2001-06-13
EP1105495B1 (de) 2005-03-16

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
AR039005A1 (es) Antigenos virales
ATE291089T1 (de) Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
EP1246644A4 (de) Induzierung zellulärer immunantworten auf humanen papillomavirus unter verwendung von peptiden und nukleinsäure-zusammensetzungen
ATE333501T1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
DE59402827D1 (de) Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
WO2005047315A3 (en) Optimized expression of hpv 58 l1 in yeast
FR11C0022I2 (fr) Production de proteine de capside de virus du papillome humain et particules de type viral
NL300323I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
NO893149L (no) Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer.
CY1110349T1 (el) Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
Panayotov et al. Oligomeric organization and strain-specific proteolytic modification of the virion M2 protein of influenza A H1N1 viruses
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
ATE473997T1 (de) Zur bildung von partikeln fähiges hbv-precore- protein
WO2002000884A3 (en) Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
EP1274851A4 (de) Für eine prozessierungskomponente aus der n-terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid
ATE288961T1 (de) Verfahren zur gewinnung von virusähnlichen partikeln auf der basis von polyomaviren
JP2002509863A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1105495

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1105495

Country of ref document: EP